Primary Hypercholesterolemia Clinical Trial
Official title:
A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.
| NCT number | NCT01879319 |
| Other study ID # | 20120356 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | |
| Last updated | |
| Start date | July 11, 2013 |
| Verified date | November 2022 |
| Source | Amgen |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).
| Status | Completed |
| Enrollment | 164 |
| Est. completion date | |
| Est. primary completion date | November 15, 2013 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility | Inclusion Criteria: - Fasting LDL-C at screening > 85 mg/dL - Fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L) Exclusion Criteria: - New York Heart Association (NYHA) III or IV heart failure - Uncontrolled cardiac arrhythmia - Uncontrolled hypertension - Type 1 diabetes or poorly controlled type 2 diabetes - Uncontrolled hypothyroidism or hyperthyroidism |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Research Site | Burnaby | British Columbia |
| Canada | Research Site | London | Ontario |
| Canada | Research Site | Pointe-Claire | Quebec |
| Canada | Research Site | Sarnia | Ontario |
| Canada | Research Site | Toronto | Ontario |
| United States | Research Site | Atlanta | Georgia |
| United States | Research Site | Atlanta | Georgia |
| United States | Research Site | Austin | Texas |
| United States | Research Site | Ayer | Massachusetts |
| United States | Research Site | Cadiz | Ohio |
| United States | Research Site | Dallas | Texas |
| United States | Research Site | Duncansville | Pennsylvania |
| United States | Research Site | Encino | California |
| United States | Research Site | Gainesville | Georgia |
| United States | Research Site | Jackson | Tennessee |
| United States | Research Site | Lansdale | Pennsylvania |
| United States | Research Site | Lewiston | Maine |
| United States | Research Site | Lexington | Kentucky |
| United States | Research Site | Manlius | New York |
| United States | Research Site | Marion | Ohio |
| United States | Research Site | Nashville | Tennessee |
| United States | Research Site | Phoenix | Arizona |
| United States | Research Site | Port Charlotte | Florida |
| United States | Research Site | Saint Augustine | Florida |
| United States | Research Site | Thousand Oaks | California |
| United States | Research Site | Tustin | California |
| United States | Research Site | Ventura | California |
| Lead Sponsor | Collaborator |
|---|---|
| Amgen |
United States, Canada,
Boccara F, Dent R, Ruilope L, Valensi P. Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. Adv Ther. 2017 Aug;34(8):1876-1896. doi: 10.1007/s12325-017-0586-8. Epub 2017 Jul 17. — View Citation
Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. — View Citation
Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1. — View Citation
Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, Lopez JAG, Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8 | Self-administration of evolocumab was assessed by a telephone interview at Weeks 4 and 8. Each participant was asked about all attempted injection(s) and if the injection was administered in part, full, or none at all. Results only include full administrations that occurred inside the prespecified visit window. | Weeks 4 and 8 | |
| Secondary | Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | Baseline and Weeks 10 and 12 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05559606 -
An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe
|
||
| Completed |
NCT03571087 -
Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT00776321 -
Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia
|
Phase 2 | |
| Recruiting |
NCT05399992 -
Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD
|
||
| Withdrawn |
NCT05798390 -
Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
|
||
| Completed |
NCT06448962 -
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
|
Phase 3 | |
| Completed |
NCT00724477 -
Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)
|
||
| Completed |
NCT00249249 -
Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels
|
Phase 3 | |
| Recruiting |
NCT05657574 -
A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT02941848 -
Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT03516955 -
Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
|
||
| Completed |
NCT01012219 -
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
|
Phase 1 | |
| Completed |
NCT05131997 -
A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A
|
Phase 3 | |
| Terminated |
NCT03433755 -
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
|
Phase 3 | |
| Completed |
NCT00867165 -
Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)
|
Phase 3 | |
| Not yet recruiting |
NCT06386419 -
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
|
Phase 4 | |
| Active, not recruiting |
NCT03952169 -
Effect of Probiotics on Lipid Management
|
N/A | |
| Terminated |
NCT01335997 -
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
|
Phase 3 | |
| Completed |
NCT02087917 -
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
|
Phase 2 | |
| Completed |
NCT00704535 -
Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)
|